GSK3359609

Unassigned

New Medicines

PD-L1-positive head and neck (or upper airways tract) cancers - in combination with pembrolizumab

Information

New molecular entity
GlaxoSmithKline
GlaxoSmithKline

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

A first-in-class anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody, that targets and binds to ICOS expressed on tumour infiltrating CD4-positive T cells
There are marked regional variations in the incidence of head and neck cancers, with rates ranging from 8 per 100,000 in the Thames and Oxford regions to 13-15 per 100,000 in Wales and in the North Western region [1].
PD-L1-positive head and neck (or upper airways tract) cancers - in combination with pembrolizumab
Intravenous infusion